Pfizer To Pay $2.3B In Bextra Off-Label Marketing Suit
Pfizer Inc. has agreed to pay $2.3 billion to settle allegations that it improperly marketed the now-defunct anti-inflammatory drug Bextra, the pharmaceutical giant disclosed Monday....To view the full article, register now.
Already a subscriber? Click here to view full article